Related Experiment Video
Updated: May 15, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
[Susceptibility to fluconazole of clinical interest yeasts: new breakpoints]
Lidia García-Agudo1, Pedro García-Martos, Pilar Marín-Casanova
1Servicio de Microbiología y Parasitología, Hospital Universitario Puerta del Mar, Spain.
Introduction:
Recently, Pfaller et al (Drug Resist Update 2010; 13:180-95), have proposed new breakpoints for determining the in vitro susceptibility to fluconazole of Candida albicans, C. parapsilosis and C. tropicalis. The aim of this study was to establish the variations in sensitivity of these species applying these breakpoints, in relation to those of the Clinical and Laboratory Standards Institute (CLSI).
Methods:
We analyzed 112 strains of Candida: 49 C. albicans, 40 C. parapsilosis and 23 C. tropicalis. Susceptibility to fluconazole was performed by the method Sensititre YeastOne. The breakpoints used to determine the minimum inhibitory concentration (MIC) were identified by CLSI and the ones proposed by Pfaller et al.
Results:
According to the CLSI criteria, all isolates were susceptible to fluconazole. MIC50 and MIC90 were 0.5 mg/L and 2 mg/L for C. albicans and C. parapsilosis, 0.5 mg/L and 1 mg/L for C. tropicalis. With the new criteria, 109 (97%) strains were susceptible. Variations were seen in C. albicans, with 3 strains (6%) susceptible dose-dependent.
Conclusions:
When applying the breakpoints recommended by Pfaller et al, and EUCAST, the number of fluconazole-susceptible strains decreased according to the CLSI criteria, especially C. albicans.
Insights
New fluconazole susceptibility breakpoints from Pfaller et al. show decreased susceptibility in Candida species, particularly Candida albicans, compared to Clinical and Laboratory Standards Institute (CLSI) criteria. This impacts antifungal resistance monitoring.
Area of Science:
- Medical Mycology
- Antimicrobial Susceptibility Testing
- Infectious Diseases
Background:
- Proposed new breakpoints for fluconazole susceptibility testing by Pfaller et al. for Candida albicans, C. parapsilosis, and C. tropicalis.
- Comparison with existing breakpoints from the Clinical and Laboratory Standards Institute (CLSI) is needed.
Purpose of the Study:
- To evaluate variations in Candida species' sensitivity to fluconazole using new proposed breakpoints.
- To compare these variations against established CLSI breakpoints.
Main Methods:
- Analysis of 112 Candida strains (49 C. albicans, 40 C. parapsilosis, 23 C. tropicalis).
- Fluconazole susceptibility testing using the Sensititre YeastOne method.
- Determination of minimum inhibitory concentrations (MICs) using both CLSI and Pfaller et al. breakpoints.
Main Results:
- Under CLSI criteria, all isolates were susceptible to fluconazole.
- Using Pfaller et al. criteria, 97% of strains remained susceptible, with 3 C. albicans strains (6%) showing dose-dependent susceptibility.
- A decrease in the number of fluconazole-susceptible strains was observed with the new breakpoints, especially for C. albicans.
Conclusions:
- The new breakpoints recommended by Pfaller et al. and EUCAST lead to a reduction in fluconazole-susceptible Candida strains compared to CLSI criteria.
- This highlights the clinical significance of updated breakpoints for accurate antifungal susceptibility interpretation.
Related Concept Videos
Antifungal Agents
Inhibitors of Bacterial DNA Synthesis
Fungal Phylum Microsporidia
Clinical Significance of Antibiotic Resistance

